When the same treatment has different response: The role of pharmacogenomics in statin therapy.

Statins, also known as HMG-CoA reductase inhibitors, are one of the most potently prescribed and thoroughly researched medications, predominantly utilized for managing cardiovascular diseases by modulating serum cholesterol levels. Despite the well-documented efficacy of statins in reducing overall mortality via attenuating the risk of cardiovascular diseases, notable interindividual variability in therapeutic responses persists as such variability could compromise the lipid-lowering efficacy of the drug, potentially increasing susceptibility to adverse effects or attenuating therapeutic outcomes.This phenomenon has catalysed a growing interest in the scientific community to explore common genetic polymorphisms within genes that encode for pivotal enzymes within the pharmacokinetic pathways of statins. In our review, we focus to provide insight into potentially clinically relevant polymorphisms associated with statins' pharmacokinetic participants and assess their consequent implications on modulating the therapeutic outcomes of statins among distinct genetic carrier • Statins pharmacokinetics involves several superfamilies of enzymes such as CYP, UGT, SLCO, ABC. • Numerous polymorphisms within genes encoding CYP, UGT, SLCO, ABC have been studied for their impact on altering statins efficacy. • Our Review provides aninsight into modulatory effect of gene polymorphisms on lipid-lowering effect of statins. [ABSTRACT FROM AUTHOR]